Darunavir is the most prescribed HIV protease inhibitor in the United States[1] and we are excited to be taking this important step in our efforts to offer it with an alternative boosting agent in a fixed-dose combination tablet, said Johan van Hoof, M.D., Therapeutic Area Head, Infectious Diseases and Vaccines, Janssen.